What is Natalizumab?
Category: Prescription Drugs
Most popular types: Tysabri Antegren
Natalizumab is a monoclonal antibody given by infusion and used in the treatment of MS and Crohn's disease. It has been shown to slow progression and reduce relapses in MS.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Multiple sclerosis | 7848 | 1498 | |
| Improve mobility | 55 | 43 | |
| General health | 35 | 21 | |
| Fatigue | 27 | 20 | |
| Crohn's disease | 24 | 2 | |
| Stiffness/spasticity | 21 | 15 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 81 | |
| Moderate | 140 | |
| Mild | 434 | |
| None | 867 |
Commonly reported side effects and conditions associated with Natalizumab
| Side effect | Patients | Percentage |
|---|---|---|
| Headaches | 97 | |
| Fatigue | 74 | |
| Tiredness | 68 | |
| Nausea | 21 | |
| Joint pain | 13 | |
| Migraine headaches | 12 |
Why patients stopped taking Natalizumab
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Doctor's advice | 309 | |
| Other | 252 | |
| Side effects too severe | 202 | |
| Did not seem to work | 161 | |
| Personal research | 61 | |
| Course of treatment ended | 34 | |
| Expense | 31 | |
| Change in health plan coverage | 18 |
Duration
Stopped taking Natalizumab
| Duration | Patients | Percentage |
|---|---|---|
| Less than 1 month | 72 | |
| 1 - 6 months | 134 | |
| 6 months - 1 year | 111 | |
| 1 - 2 years | 172 | |
| 2 - 5 years | 194 | |
| 5 - 10 years | 53 | |
| 10 years or more | 12 |
What people switch to and from
Patients started taking Natalizumab after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Glatiramer acetate (Copaxone) | 96 | |
| Interferon beta-1a IM Injection (Avonex) | 57 | |
| Interferon beta-1a SubQ injection (Rebif) | 54 | |
| Dimethyl fumarate (Tecfidera) | 45 | |
| Fingolimod (Gilenya) | 38 |
Patients stopped taking Natalizumab and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Fingolimod (Gilenya) | 59 | |
| Dimethyl fumarate (Tecfidera) | 56 | |
| Ocrelizumab (Ocrevus) | 50 | |
| Alemtuzumab (Lemtrada) | 22 | |
| Rituximab (Rituxan) | 21 |
Last updated: